Sumitomo Pharma revenue and financials
¥1,610.00Change from previous close: −0.68%Absolute change: −¥11.00
In the fiscal year ended March 2026, Sumitomo Pharma reported revenue of ¥453.29B (+13.66% year over year). Net income was ¥106.87B, a net margin of 23.6%.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +13.66%
- FY to Mar 2026 vs FY to Mar 2025
- Net income growth
- +352.17%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- 23.6%
- FY to Mar 2025: 5.9%
Financial data
Amounts in millions of JPY; per-share values in JPY; shares in millions.
| Item | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 | FY to Mar 2022 |
|---|---|---|---|---|
| Operating cash flow | 16,500 | -241,893 | 11,937 | 31,239 |
| Depreciation and amortization | 25,562 | 37,765 | 41,263 | 38,348 |
| Capital expenditure | -13,030 | -15,730 | -12,742 | -13,494 |
| Investing cash flow | 99,754 | 33,036 | 52,419 | -18,278 |
| Financing cash flow | -108,836 | 77,851 | -146,817 | -21,426 |
| Dividends paid | -3.0 | -2,792 | -11,125 | -11,126 |
| Debt issued | 139,487 | 0.0 | — | 0.0 |
| Debt repaid | -70,000 | 0.0 | -20,060 | -4,960 |
| Effect of exchange rates | -177 | 15,440 | 24,090 | 17,751 |
| Net change in cash | 7,418 | -131,006 | -82,461 | -8,465 |
| Free cash flow | 3,470 | -257,623 | -805 | 17,745 |